Defining Optimal Immunotherapies for Type 1 Diabetes / Novartis Foundation Symposium (PDF)
Novartis Foundation Symposium, Volume 292
(Sprache: Englisch)
* This book is a comprehensive and up-to-date account of where we
stand in immunological strategies for preventing or treating type 1
diabetes (T1D).
* Brings together contributions from the leaders in the arena of
clinical immunotherapy, not limited...
stand in immunological strategies for preventing or treating type 1
diabetes (T1D).
* Brings together contributions from the leaders in the arena of
clinical immunotherapy, not limited...
sofort als Download lieferbar
eBook (pdf)
Fr. 155.00
inkl. MwSt.
- Kreditkarte, Paypal, Rechnung
- Kostenloser tolino webreader
Produktdetails
Produktinformationen zu „Defining Optimal Immunotherapies for Type 1 Diabetes / Novartis Foundation Symposium (PDF)“
* This book is a comprehensive and up-to-date account of where we
stand in immunological strategies for preventing or treating type 1
diabetes (T1D).
* Brings together contributions from the leaders in the arena of
clinical immunotherapy, not limited to the diabetes field
exclusively, in order to delineate a road-map that would lead to
future clinical trials.
* The book integrates information from human and animal
studies.
* The book considers T1D within the broader context of autoimmune
disease.
* The format contains several discussions, which address specific
questions and provides guidelines for future strategies and
solutions for discovering a cure.
stand in immunological strategies for preventing or treating type 1
diabetes (T1D).
* Brings together contributions from the leaders in the arena of
clinical immunotherapy, not limited to the diabetes field
exclusively, in order to delineate a road-map that would lead to
future clinical trials.
* The book integrates information from human and animal
studies.
* The book considers T1D within the broader context of autoimmune
disease.
* The format contains several discussions, which address specific
questions and provides guidelines for future strategies and
solutions for discovering a cure.
Inhaltsverzeichnis zu „Defining Optimal Immunotherapies for Type 1 Diabetes / Novartis Foundation Symposium (PDF)“
1. Michael Rutter Introduction: whither gene-environment interactions? 2. Rudolf Uher Gene-environment interaction: overcoming methodological challenges Discussion 3. Marco Battaglia, Cecilia Marino, Michel Maziade, Massimo Molteni and Francesca D'Amato Gene-environment interaction and behavioural disorders: a developmental perspective based on endophenotypes Discussion 4. Naomi R. Wray, William L. Coventry, Michael R. James, Grant W. Montgomery, Lindon J. Eaves and Nicholas G. Martin Use of monozygotic twins to investigate the relationship between 5HTTLPR genotype, depression and stressful life events: an application of Item Response Theory Discussion Appendix General discussion I 5. Harold Snieder, Xiaoling Wang, Vasiliki Lagou, Brenda W. J. H. Penninx, Harriëtte Riese and Catharina A. Hartman Role of gene-stress interactions in gene-finding studies Discussion 6. Kenneth A. Dodge Practice and public policy in the era of gene-environment interactions Discussion 7. Kristi B. Adamo and Frédérique Tesson Gene-environment interaction and the metabolic syndrome Discussion General discussion II 8. Stephen P. Robertson and Richie Poulton Longitudinal studies of gene-environment interaction in common diseases--good value for money? Discussion 9. Kee-Seng Chia Gene-environment interactions in breast cancer Discussion 10. Malak Kotb, Nourtan Abdeltawab, Ramy Aziz, Sarah Rowe, Robert W. Williams and Lu Lu Unbiased forward genetics and systems biology approaches to understanding how gene-environment interactions work to predict susceptibility and outcomes of infections Discussion 11. Steven R. Kleeberger and Hye-Youn Cho Gene-environment interactions in environmental lung diseases Discussion General discussion III 12. Fernando D. Martinez Gene-environment interaction in complex diseases: asthma as an illustrative case Discussion 13. Michael Rutter Conclusions: taking stock and looking ahead Glossary Index of contributors Subject index
Autoren-Porträt
The Novartis Foundation is an international scientific and educational charity which promotes the study and general knowledge of science and in particular encourages international co-operation in scientific research.
Bibliographische Angaben
- 2008, 1. Auflage, 222 Seiten, Englisch
- Herausgegeben: Gregory R. Bock, Jamie A. Goode
- Verlag: John Wiley & Sons
- ISBN-10: 0470697415
- ISBN-13: 9780470697412
- Erscheinungsdatum: 14.09.2008
Abhängig von Bildschirmgrösse und eingestellter Schriftgrösse kann die Seitenzahl auf Ihrem Lesegerät variieren.
eBook Informationen
- Dateiformat: PDF
- Grösse: 1.99 MB
- Mit Kopierschutz
Sprache:
Englisch
Kopierschutz
Dieses eBook können Sie uneingeschränkt auf allen Geräten der tolino Familie lesen. Zum Lesen auf sonstigen eReadern und am PC benötigen Sie eine Adobe ID.
Kommentar zu "Defining Optimal Immunotherapies for Type 1 Diabetes / Novartis Foundation Symposium"
0 Gebrauchte Artikel zu „Defining Optimal Immunotherapies for Type 1 Diabetes / Novartis Foundation Symposium“
Zustand | Preis | Porto | Zahlung | Verkäufer | Rating |
---|
Schreiben Sie einen Kommentar zu "Defining Optimal Immunotherapies for Type 1 Diabetes / Novartis Foundation Symposium".
Kommentar verfassen